biotech
biotech Articles
The January 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
Editas Medicine shares were crushed on Tuesday after the company announced that its president and chief executive, Katrine Bosley, would be stepping down from these roles effective March 1.
Published:
Last Updated:
Lexicon shares fell on Friday after the FDA voted to approve the firm’s type 1 diabetes treatment. Although the result from this committee was mixed, it seems to be a case of sell the news.
Published:
Last Updated:
Immunomedics shares were crushed on Friday after the firm received disappointing news from the FDA on its breast cancer treatment.
Published:
Last Updated:
Aptinyx shares were absolutely crushed on Wednesday after the firm reported midstage results from its clinical study in patients with painful diabetic peripheral neuropathy.
Published:
Last Updated:
The December 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
Akorn shares dipped on Wednesday after the company received a warning letter from the FDA regarding its Decatur, Illinois, manufacturing facility.
Published:
Last Updated:
Moderna shares made a handy gain early Tuesday after the company announced updates to several of its immuno-oncology and rare disease programs and outlined its 2019–2020 corporate objectives.
Published:
Last Updated:
Clinical-stage biopharmaceutical company Alector has filed with the SEC for its initial public offering.
Published:
Last Updated:
Loxo shares made a massive gain on Monday after it was announced that the firm would be acquired by Eli Lilly. The transaction is not subject to any financing condition and is expected to close by...
Published:
Last Updated:
Axsome shares absolutely exploded on Monday after the company announced that its midstage trial in patients with major depressive disorder met its primary endpoint.
Published:
Last Updated:
Clinical-stage biopharmaceutical company Poseida Therapeutics has filed with the SEC regarding its initial public offering.
Published:
Last Updated:
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the first quarter of 2019.
Published:
Last Updated:
Ultragenyx Pharma shares made a handy gain to close out the week after the company announced positive results from its midstage trial for the treatment of glycogen storage disease type Ia.
Published:
Last Updated:
A prominent health care analyst has identified his top health care stock picks for 2019, and some are somewhat speculative.
Published:
Last Updated: